Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SKB 571

Next Previous
Drug Profile

SKB 571

Alternative Names: MK-2750; SKB-571

Latest Information Update: 20 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Kelun Pharmaceutical Research Institute
  • Developer Merck & Co; Sichuan Kelun Pharmaceutical Research Institute
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 19 Jan 2026 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in China (Parenteral) (NCT07230405)
  • 29 Dec 2025 Sichuan Kelun-Biotech Biopharmaceutical plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) (Parenteral, Injection) in February 2026 (NCT07308106)
  • 18 Aug 2025 Sichuan Kelun Pharmaceutical Research Institute plans a phase-II trial for Solid tumours in China (Parenteral) (Sichuan Kelun Pharmaceutical Research Institute pipeline; September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top